KYMR (STOCKS)
Kymera Therapeutics, Inc. Common Stock
$114.420000
+0.390000 (+0.34%)
Prev close: $114.030000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Nello Mainolfi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $10,803.11M
- Employees
- 225
- P/E (TTM)
- -35.17
- P/B (TTM)
- 6.25
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
16
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.62 | $-0.73 | +0.1073 | +14.75% |
|
Mar 2026 (Q1)
|
$-0.71 | $-0.90 | +0.1893 | +21.05% |
|
Dec 2025 (Q4)
|
$-0.97 | $-0.81 | -0.1578 | -19.43% |
|
Sep 2025 (Q3)
|
$-0.94 | $-0.82 | -0.1200 | -14.63% |
Financial Statements
| Revenues | $105.00M |
| Benefits Costs and Expenses | $319.66M |
| Cost Of Revenue | $105.00M |
| Costs And Expenses | $414.95M |
| Gross Profit | $0.00 |
| Operating Expenses | $455.18M |
| Research and Development | $375.57M |
| Other Operating Expenses | $79.61M |
| Operating Income/Loss | -$350.18M |
| Income/Loss From Continuing Operations After Tax | -$299.60M |
| Income/Loss From Continuing Operations Before Tax | -$214.66M |
| Net Income/Loss | -$299.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$299.60M |
| Net Income/Loss Available To Common Stockholders, Basic | -$299.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.25 |
| Diluted Earnings Per Share | -$3.25 |
| Basic Average Shares | 186,995,218 |
| Diluted Average Shares | 186,995,218 |
| Assets | $1.65B |
| Current Assets | $737.27M |
| Noncurrent Assets | $908.18M |
| Fixed Assets | $39.97M |
| Other Non-current Assets | $868.21M |
| Liabilities | $136.19M |
| Current Liabilities | $71.33M |
| Accounts Payable | $8.92M |
| Other Current Liabilities | $62.41M |
| Noncurrent Liabilities | $64.86M |
| Equity | $1.51B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.51B |
| Liabilities And Equity | $1.65B |
| Net Cash Flow From Operating Activities | -$236.76M |
| Net Cash Flow From Operating Activities, Continuing | -$236.76M |
| Net Cash Flow From Investing Activities | -$752.49M |
| Net Cash Flow From Investing Activities, Continuing | -$752.49M |
| Net Cash Flow From Financing Activities | $777.92M |
| Net Cash Flow From Financing Activities, Continuing | $777.92M |
| Net Cash Flow | -$211.34M |
| Net Cash Flow, Continuing | -$211.34M |
| Comprehensive Income/Loss | -$307.04M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$307.04M |
| Other Comprehensive Income/Loss | -$89.61M |